A Phase 3 interventional study of Dexamethasone and Prednisolone in Cataract, sponsored by ICON Bioscience Inc. Completed at 11 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by ICON Bioscience Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.
Among the 34 studies testing dexamethasone in Cataract, this one is the 8th largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 4th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 10 · Phase 4 18
First in 2004; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 50 across the 34 interventional studies. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 34 have an industry lead sponsor. The 10 most frequent:
ICON Bioscience Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
ICON Bioscience Inc has 4 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing dexamethasone in Cataract, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups
The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
dexamethasone depot 517 mcg
Drug: Dexamethasone
prednisolone drops 1%
Drug: Prednisolone
depot intracameral
Also known as: Dexycu
Prednisolone eye drops 1%
Also known as: standard of care
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent Adverse Events were defined as events that started after the study drug administration, and occurred before termination of the study, or were present before study drug administration and worsened after dose administration.
Time frame: Baseline to postoperative day 90/ early termination
Intraocular Pressure Measurement
Intraocular Pressure was measured by Goldmann applanation tonometry.
Time frame: Baseline, Postoperative (POD) 1, POD 8, POD 30, POD 90/Early termination
Visual Acuity in Study Eye
Visual Acuity assessed by the Snellen chart, was expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1
Time frame: Baseline, Postoperative (POD) 1, POD 8, POD 30, POD 90/Early termination
Slit Lamp Biomicroscopy - Conjunctival Hyperemia Grade
Slit lamp biomicroscopy of the anterior chamber was performed using a slit beam of 1-mm height and 1-mm width with maximum luminance through the highest-powered lens using the Investigator's standard slit lamp equipment and procedure. Conjunctiva hyperemia slit lamp results were summarized by treatment group and time point.
Time frame: Baseline, Postoperative (POD) 1, POD 8, POD 30, POD 90/Early termination
Slit Lamp Biomicroscopy - Cornea Edema Grade
Slit lamp biomicroscopy of the anterior chamber was performed using a slit beam of 1-mm height and 1-mm width with maximum luminance through the highest-powered lens using the Investigator's standard slit lamp equipment and procedure. Cornea edema slit lamp results in the study eye were summarized by treatment group and time point.
Time frame: Baseline, Postoperative (POD) 1, POD 8, POD 30, POD 90/Early termination
Summary of Concomitant Medications Used in the Study Eye or Both Eyes
Time frame: Baseline, Postoperative (POD) 1, POD 8, POD 30, POD 90/Early termination
Changes in the Corneal Endothelial Cell Count
Corneal Endothelial Cell Density was measured by specular microscopy.
Time frame: Baseline, Postoperative day 90/Early termination
Optic Disc Cup-disc Ratio for the Study Eye
Calculated as the ratio of the diameter of the depression (cup) to that of the optical nerve head (disc).
Time frame: Baseline, POD 90/Early termination
Dilated Opthalmoscopy Findings - Optic Disc (Study Eye)
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's optic disc
Time frame: Baseline, POD 90/Early termination
Dilated Opthalmoscopy Findings - Retina (Study Eye)
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's retina
Time frame: Baseline, POD 90/Early termination
Dilated Opthalmoscopy Findings - Macula (Study Eye)
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's macula.
Time frame: Baseline, POD 90/Early termination
Dilated Opthalmoscopy Findings - Choroid (Study Eye)
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's choroid
Time frame: Baseline, POD 90/Early termination
Dilated Opthalmoscopy Findings - Vitreous (Study Eye)
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's vitreous
Time frame: Baseline, POD 90/Early termination
The first patient was enrolled into the study on 06 November 2015 and the last patient completed the study on 16 August 2016.
| Milestone | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Started | 126 | 55 |
| Completed | 122 | 52 |
| Not completed | 4 | 3 |
Treatment-emergent Adverse Events were defined as events that started after the study drug administration, and occurred before termination of the study, or were present before study drug administration and worsened after dose administration.
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Ocular events: study eye — Any TEAE | 53 | 13 |
| Ocular events: study eye — Serious TEAE | 1 | 0 |
| Ocular events: study eye — No TEAE | 72 | 42 |
| Ocular events: fellow eye — Any TEAE | 12 | 4 |
| Ocular events: fellow eye — Serious TEAE | 0 | 0 |
| Ocular events: fellow eye — No TEAE | 114 | 51 |
| Systemic events — Any TEAE | 10 | 6 |
| Systemic events — Serious TEAE | 2 | 0 |
| Systemic events — No TEAE | 114 | 49 |
Intraocular Pressure was measured by Goldmann applanation tonometry.
| mmHG | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) | 15.1 ± 2.94 | 14.4 ± 2.71 |
| Post Operative Day 1 | 19.1 ± 6.54 | 17.5 ± 6.44 |
| Post Operative Day 8 | 15.0 ± 4.7 | 15.1 ± 3.64 |
| Post Operative Day 30 | 13.8 ± 3.2 | 14.1 ± 3.57 |
| Post Operative Day 90/End of Treatment | 13.0 ± 2.89 | 12.7 ± 2.93 |
Visual Acuity assessed by the Snellen chart, was expressed as the logarithm of the minimum angle of resolution (logMAR), and could range from 0 (representing 20/20 vision) to 1
| LogMar | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) | .292 ± 0.1913 | .355 ± .2557 |
| Post Operative Day 1 | .249 ± .1398 | .327 ± .2129 |
| Post Operative Day 8 | .073 ± .1353 | .073 ± .1746 |
| Post Operative Day 30 | .039 ± .0952 | .040 ± .1350 |
| Post Operative Day 90/End of Treatment | .040 ± .1012 | .047 ± .1150 |
Slit lamp biomicroscopy of the anterior chamber was performed using a slit beam of 1-mm height and 1-mm width with maximum luminance through the highest-powered lens using the Investigator's standard slit lamp equipment and procedure. Conjunctiva hyperemia slit lamp results were summarized by treatment group and time point.
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Baseline — 0 (Absent) | 124 | 55 |
| Baseline — 1 (Mild) | 1 | 0 |
| Baseline — 2 (Moderate) | 1 | 0 |
| Baseline — 3 (Severe) | 0 | 0 |
| Baseline — No value | 0 | 0 |
| Postoperative day 1 — 0 (Absent) | 103 | 45 |
| Postoperative day 1 — 1 (Mild) | 21 | 10 |
| Postoperative day 1 — 2 (Moderate) | 2 | 0 |
| Postoperative day 1 — 3 (Severe) | 0 | 0 |
| Postoperative day 1 — No value | 0 | 0 |
| Postoperative day 8 — 0 (Absent) | 115 | 45 |
| Postoperative day 8 — 1 (Mild) | 11 | 8 |
| Postoperative day 8 — 2 (Moderate) | 0 | 0 |
| Postoperative day 8 — 3 (Severe) | 0 | 0 |
| Postoperative day 8 — No value | 0 | 2 |
| Postoperative day 30 — 0 (Absent) | 107 | 44 |
| Postoperative day 30 — 1 (Mild) | 14 | 8 |
| Postoperative day 30 — 2 (Moderate) | 2 | 0 |
| Postoperative day 30 — 3 (Severe) | 0 | 0 |
| Postoperative day 30 — No value | 3 | 3 |
| Postoperative day 90/End of Treatment — 0 (Absent) | 119 | 50 |
| Postoperative day 90/End of Treatment — 1 (Mild) | 4 | 2 |
| Postoperative day 90/End of Treatment — 2 (Moderate) | 0 | 0 |
| Postoperative day 90/End of Treatment — 3 (Severe) | 0 | 0 |
| Postoperative day 90/End of Treatment — No value | 3 | 3 |
Slit lamp biomicroscopy of the anterior chamber was performed using a slit beam of 1-mm height and 1-mm width with maximum luminance through the highest-powered lens using the Investigator's standard slit lamp equipment and procedure. Cornea edema slit lamp results in the study eye were summarized by treatment group and time point.
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Baseline — 0 (Absent) | 126 | 54 |
| Baseline — 1 (Mild) | 0 | 0 |
| Baseline — 2 (Moderate) | 0 | 0 |
| Baseline — 3 (Severe) | 0 | 0 |
| Baseline — No value | 0 | 1 |
| Postoperative day 1 — 0 (Absent) | 74 | 37 |
| Postoperative day 1 — 1 (Mild) | 43 | 15 |
| Postoperative day 1 — 2 (Moderate) | 9 | 3 |
| Postoperative day 1 — 3 (Severe) | 0 | 0 |
| Postoperative day 1 — No value | 0 | 0 |
| Postoperative day 8 — 0 (Absent) | 109 | 48 |
| Postoperative day 8 — 1 (Mild) | 16 | 6 |
| Postoperative day 8 — 2 (Moderate) | 0 | 0 |
| Postoperative day 8 — 3 (Severe) | 0 | 0 |
| Postoperative day 8 — No value | 1 | 1 |
| Postoperative day 30 — 0 (Absent) | 121 | 52 |
| Postoperative day 30 — 1 (Mild) | 0 | 0 |
| Postoperative day 30 — 2 (Moderate) | 2 | 0 |
| Postoperative day 30 — 3 (Severe) | 0 | 0 |
| Postoperative day 30 — No value | 3 | 3 |
| Postoperative day 90/End of Treatment — 0 (Absent) | 123 | 52 |
| Postoperative day 90/End of Treatment — 1 (Mild) | 0 | 0 |
| Postoperative day 90/End of Treatment — 2 (Moderate) | 0 | 0 |
| Postoperative day 90/End of Treatment — 3 (Severe) | 0 | 0 |
| Postoperative day 90/End of Treatment — No value | 3 | 3 |
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Patients reporting at least one concomitant medica | 124 | 55 |
| Antiseptics and disinfectants | 1 | 1 |
| Anesthetics | 4 | 1 |
| Psycholeptics | 2 | 1 |
| Ophthalmologicals | 124 | 55 |
| Thyroid therapy | 0 | 1 |
Corneal Endothelial Cell Density was measured by specular microscopy.
| cells/mm^2 | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Baseline | 2483.66 ± 351.819 | 2398.33 ± 384.092 |
| Postoperative day 90/End of treatment | 2141.77 ± 522.327 | 2106.39 ± 517.938 |
| Change from Baseline | -334.60 ± 415.071 | -288.83 ± 376.775 |
Calculated as the ratio of the diameter of the depression (cup) to that of the optical nerve head (disc).
| ratio | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) | .31 ± .142 | .32 ± .135 |
| Postoperative day 90/End of treatment | .31 ± .131 | .33 ± .143 |
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's optic disc
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) — Normal | 115 | 52 |
| Screening (Baseline) — Abnormal | 2 | 1 |
| Screening (Baseline) — Not analyzed | 9 | 2 |
| Postoperative day 90/End of treatment — Normal | 119 | 50 |
| Postoperative day 90/End of treatment — Abnormal | 2 | 1 |
| Postoperative day 90/End of treatment — Not analyzed | 5 | 4 |
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's retina
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) — Normal | 120 | 51 |
| Screening (Baseline) — Abnormal | 5 | 4 |
| Screening (Baseline) — Not analyzed | 1 | 0 |
| Postoperative day 90/End of treatment — Normal | 118 | 50 |
| Postoperative day 90/End of treatment — Abnormal | 5 | 1 |
| Postoperative day 90/End of treatment — Not analyzed | 3 | 4 |
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's macula.
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) — Normal | 109 | 44 |
| Screening (Baseline) — Abnormal | 15 | 11 |
| Screening (Baseline) — Not analyzed | 2 | 0 |
| Postoperative day 90/End of treatment — Normal | 107 | 39 |
| Postoperative day 90/End of treatment — Abnormal | 16 | 12 |
| Postoperative day 90/End of treatment — Not analyzed | 3 | 4 |
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's choroid
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) — Normal | 124 | 54 |
| Screening (Baseline) — Abnormal | 0 | 0 |
| Screening (Baseline) — Not analyzed | 2 | 1 |
| Postoperative day 90/End of treatment — Normal | 122 | 50 |
| Postoperative day 90/End of treatment — Abnormal | 1 | 0 |
| Postoperative day 90/End of treatment — Not analyzed | 3 | 5 |
The number and percentage of patients with normal or abnormal findings from dilated opthalmoscopy examination of the study eye's vitreous
| Participants | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Screening (Baseline) — Normal | 104 | 49 |
| Screening (Baseline) — Abnormal | 21 | 5 |
| Screening (Baseline) — Not analyzed | 1 | 1 |
| Postoperative day 90/End of treatment — Normal | 107 | 44 |
| Postoperative day 90/End of treatment — Abnormal | 16 | 7 |
| Postoperative day 90/End of treatment — Not analyzed | 3 | 4 |
Collected over Adverse event data was collected from screening until postoperative day 90/end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexamethasone Depot | 0/126 (0%) | 3/126 (2.4%) | 23/126 (18.3%) |
| Prednisolone Drops 1% (Standard of Care) | 0/55 (0%) | 0/55 (0%) | 6/55 (10.9%) |
| Event | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Diabetic retinopathyEye disorders | 1/126 | 0/55 |
| Loss of consciousnessNervous system disorders | 1/126 | 0/55 |
| Abdominal herniaGastrointestinal disorders | 1/126 | 0/55 |
| Event | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) |
|---|---|---|
| Intraocular pressure increasedInvestigations | 14/126 | 2/55 |
| HeadacheNervous system disorders | 1/126 | 4/55 |
| IritisEye disorders | 8/126 | 0/55 |
| Age, Categorical(Participants) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 17 | 51 |
| >=65 years | 92 | 38 | 130 |
| Sex: Female, Male(Participants) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| Female | 67 | 31 | 98 |
| Male | 59 | 24 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 1 | 10 |
| Not Hispanic or Latino | 117 | 54 | 171 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 1 | 12 |
| White | 111 | 52 | 163 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Region of Enrollment(Participants) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| United States | 126 | 55 | 181 |
| Study Eye(study eye) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| OD (Right eye) | 67 | 27 | 94 |
| OS (Left eye) | 59 | 28 | 87 |
| Best Corrected Visual Acuity(LogMar) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| study eye number | .292 ± .1913 | .355 ± .2557 | .311 ± .2141 |
| fellow eye number | .126 ± .1394 | .176 ± .2123 | .141 ± .1660 |
| Corneal Endothelial Cell Density - Specular Microscopy(cells/mm^2) | Dexamethasone Depot | Prednisolone Drops 1% (Standard of Care) | Total |
|---|---|---|---|
| Mean | 2491.91 ± 346.365 | 2398.33 ± 384.092 | 2463.15 ± 359.902 |
3 further baseline measures are reported on the registry.
Ran from Nov 2015 to primary completion in Aug 2016, 9 months.
Results were first posted in Jun 2018, 1 year 10 months after primary completion.
Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 9 months is below that.
Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
ICON Bioscience Inc